NEW YORK (GenomeWeb) — CancerLinQ has entered into an agreement with Tempus and Precision HealthAI to accelerate development and delivery of high-quality, deidentified clinical databases, CancerLinQ said yesterday.
The databases are intended for use by CancerLinQ, a non-profit subsidiary of the American Society of Clinical Oncology, as well as its oncologist subscribers, partners, and the broader cancer community. They will be made available through the core CancerLinQ quality improvement platform and the organization’s CancerLinQ Discovery service.
Under the new license, CancerLinQ will retain its non-profit status and remain responsible for data integration and providing a platform of meaningful tools and reports to participating oncologists and oncology care sites. Tempus and Precision HealthAI will be responsible for further structuring this dataset to put it to work for the benefit of patients.
Tempus and Precision HealthAI will bring these deidentified datasets to industry partners to produce practical applications such as targeted therapies, more efficient clinical trials, and data-driven analyses to help determine which therapies are producing the greatest patient benefit. Royalties from this license will help to support ASCO’s CancerLinQ initiative.
“At Tempus, we have built a platform to help usher in an era of precision medicine, empowering physicians with the tools and information they need to improve patient outcomes,” Tempus Founder and CEO Eric Lefkofsky said in a statement. “Building on the vast network that CancerLinQ has established, our team will apply sophisticated technology tools to this large body of clinical and molecular data to help power cutting-edge research and produce actionable clinical insights.”
Romesh Wadhwani, chairman of Precision HealthAI, noted in a statement that his company is developing “an innovative AI platform for the management, delivery, and use of clinical data,” and that applying its technology to deidentified CancerLinQ data “will help the broader community to accelerate research and the development and administration of new therapies.”